Targeted failure of the week. Post 108. Iclusig

Ariad Pharmaceuticals Inc said the U.S. Food and Drug Administration had placed a partial hold on patient enrollment for trials of its cancer drug Iclusig after a number of patients taking the drug experienced blood clots and heart damage.

Ariad shares plunged as much as 77 percent to $4.00 in heavy trading -- their lowest in three years.
The company said it paused enrollment in the trials after it reviewed new data from a pivotal mid-stage trial testing the drug to treat two forms of blood cancer.